Guggenheim analyst Yatin Suneja reiterated a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of $12.00. The company’s shares closed today at $8.92.

According to TipRanks, Suneja is a 4-star analyst with an average return of 5.2% and a 44.67% success rate. Suneja covers the Healthcare sector, focusing on stocks such as Neurocrine, Regeneron, and Axsome Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Phathom Pharmaceuticals with a $17.67 average price target, a 98.09% upside from current levels. In a report released today, Stifel Nicolaus also reiterated a Buy rating on the stock with a $28.00 price target.

PHAT market cap is currently $328.1M and has a P/E ratio of -0.89.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PHAT in relation to earlier this year. Last month, James Topper, a Director at PHAT bought 3,780.00 shares for a total of $14,590.80.